©2024 Stanford Medicine
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema
Not Recruiting
Trial ID: NCT01893879
Purpose
This randomized clinical trial studies an investigational drug in preventing lymphedema in
patients at high risk after undergoing axillary lymph node dissection. The study drug may
prevent lymphedema in patients undergoing axillary lymph node dissection.
Official Title
Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients
Stanford Investigator(s)
Stanley G. Rockson, MD
Allan and Tina Neill Professor of Lymphatic Research and Medicine
Eligibility
Inclusion Criteria:
- Axillary lymph node dissection within the preceding 12 months
Exclusion Criteria:
- Patients with active cancer
- Patients with lymphedema
- Infection or bleeding tendency
- Patients with medical contraindications to nonsteroidal anti-inflammatory drugs
(NSAIDs), including history of allergies, know gastrointestinal intolerance
- Other serious systemic illness (e.g., renal failure, hepatic dysfunction, congestive
heart failure, neurological or psychological impairment) that would impair the
patients' ability to participate
- Persons not competent to consent
- Patients on aspirin therapy
- Minors (< 18 years of age)
- Pregnant and/or lactating women
- Males
Intervention(s):
other: laboratory biomarker analysis
drug: placebo for study drug
drug: (RS)2-(3-benzoylphenyl)-propionic acid
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305